Prolonged inhibition of cholesterol synthesis by atorvastatin inhibits apo B-100 and triglyceride secretion from HepG2 cells

Atherosclerosis

Volumn 157, Issue 1, 2001, Pages 107-115

  Funatsu, T ^a   Suzuki, K ^a   Goto, M ^a   Arai, Y ^a   Kakuta, H ^a   Tanaka, H ^a   Yasuda, S ^a   Ida, M ^a   Nishijima, S ^a   Miyata, K ^a  

^a Inst for Drug Discovery Research   (Japan)

Author keywords

Apo B; Atorvastatin; Cholesterol synthesis; HepG2 cells; HMG CoA reductase inhibitor; Simvastatin

Indexed keywords

APOLIPOPROTEIN B; ATORVASTATIN; BMS 201038; CARRIER PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; MESSENGER RNA; MEVALONOLACTONE; SIMVASTATIN; UNCLASSIFIED DRUG;

ARTICLE; CELL LINE; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG INHIBITION; HUMAN; HUMAN CELL; LIPID TRANSPORT; LIPOGENESIS; PRIORITY JOURNAL; TREATMENT OUTCOME;

ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEIN B-100; APOLIPOPROTEINS B; CELL LINE; CHOLESTEROL; DOWN-REGULATION; HEPTANOIC ACIDS; HUMANS; LIVER; PYRROLES; TIME FACTORS; TRIGLYCERIDES;

EID: 0034971209     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(00)00714-0     Document Type: Article

References (46)

1. Hypocholesterolemic actions of atorvastatin are associated with alterations on hepatic cholesterol metabolism and lipoprotein composition in the guinea pig
2. Hep-G2 cells and primary rat hepatocytes differ in their response to inhibitors of HMG-CoA reductase
3. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor
4. A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia
5. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)
6. A brief review paper of the efficacy and safety of atorvastatin in early clinical trials
7. Lipid-lowering activity of atorvastatin and lovastatin in rodent species: Triglyceride-lowering in rats correlates with efficacy in LDL animal models
8. Inhibition of HMG-CoA reductase by atorvastatin decreases both VLDL and LDL apolipoprotein B production in miniature pigs
9. The HMG-CoA reductase inhibitor atorvastatin increases the fractional clearance rate of postprandial triglyceride-rich lipoproteins in miniature pigs
10. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia
11. Evidence for separate pathways of chylomicron and very low-density lipoprotein assembly and transport by rat small intestine
12. ApoB-100 secretion by HepG2 cells is regulated by the rate of triglyceride biosynthesis but not by intracellular lipid pools
13. Evidence for a lack of regulation of the assembly and secretion of apolipoprotein B-containing lipoprotein from HepG2 cells by cholesteryl ester
14. Exogenous VLDL stimulates apolipoprotein B secretion from HepG2 cells by both pre- and post-translational mechanisms
15. Evaluation of cultured hamster hepatocytes as an experimental model for the study of very low density lipoprotein secretion
16. An inhibitor of squalene epoxidase, NB-598, suppresses the secretion of cholesterol and triacylglycerol and simultaneously reduces apolipoprotein B in HepG2 cells
17. Role of the neutral lipid accessible pool in the regulation of secretion of apoB-100 lipoprotein particles by HepG2 cells
18. Regulation of apoB secretion from HepG2 cells: Evidence for a critical role for cholesteryl ester synthesis in the response to a fatty acid challenge
19. Regulation of apolipoprotein B production and secretion in response to the change of intracellular cholesteryl ester contents in rabbit hepatocytes
20. The effect of low density lipoproteins, cholesterol, and 25-hydroxycholesterol on apolipoprotein B gene expression in HepG2 cells
21. Nascent VLDL phospholipid composition is altered when phosphatidylcholine biosynthesis is inhibited: Evidence for a novel mechanism that regulates VLDL secretion
22. Regulated intracellular degradation of apolipoprotein B in semipermeable HepG2 cells
23. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and hepatic apolipoprotein B secretion
24. Prolonged inhibition of cholesterol synthesis explains the efficacy of atorvastatin
25. Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen
26. Absence of microsomal triglyceride transfer protein in individuals with abetalipoproteinemia
27. Purification and characterization of microsomal triglyceride and cholesteryl ester transfer protein from bovine liver microsomes
28. An MTP inhibitor that normalizes atherogenic lipoprotein levels in WHHL rabbits
29. Receptor-mediated endocytosis of low-density lipoprotein in cultured cells
30. Non-lipid-related effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors
31. Effect of simvastatin (MK-733) on the regulation of cholesterol synthesis in Hep G2 cells
32. Microsomal triglyceride transfer protein (MTP) regulation in HepG2 cells: Insulin negatively regulates MTP gene expression
33. Enzymatic determination of triglyceride, free cholesterol, and total cholesterol in tissue lipid extracts
34. Real time quantitative PCR
35. Transcriptional regulation of muscle-specific genes during myoblast differentiation
36. Role of cholesterol in regulating apolipoprotein B secretion by the liver
37. Regulation of hepatic secretion of apolipoprotein B-containing lipoproteins: Information obtained from cultured liver cells
38. Lipid balance in HepG2 cells: Active synthesis and impaired mobilization
39. Hepatic responses to inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase: A comparison of atorvastatin and simvastatin
40. Hepatic expression of the catalytic subunit of the apolipoprotein B mRNA editing enzyme (apobec-1) ameliorates hypercholesterolemia in LDL receptor-deficient rabbits
41. Cholesterol metabolism in cultured hamster hepatocytes
42. Role of cholesterol ester mass in regulation of secretion of ApoB100 lipoprotein particles by hamster hepatocytes and effects of statins on that relationship
43. Pharmacologic profile of YM548, a novel HMG-CoA reductase inhibitor, in HepG2 cells
44. Microsomal triacylglycerol transfer protein prevents presecretory degradation of apolipoprotein B-100. A dithiothreitol-sensitive protease is involved
45. Differential regulation of apolipoprotein B secretion from HepG2 cells by two HMG-CoA reductase inhibitors, atorvastatin and simvastatin
46. Effects of atorvastatin on the intracellular stability and secretion of apolipoprotein B in HepG2 cells